datasheet1_Association of 5-Hydroxytryptamine 3 Receptor Antagonists With the Prognosis of Liver Failure.doc
Liver failure is a severe clinical syndrome with high mortality. 5-Hydroxytryptamine 3 receptor antagonists (5-HT3RAs) can reduce liver damage in animal models. We investigated whether 5-HT3RAs may improve the prognosis of liver failure. We analyzed the 28 and 90 days mortality of liver failure patients in relation to the use of 5-HT3RAs using data from a tertiary hospital in northwest China. According to the use of 5-HT3RAs, 419 patients with liver failure (46 acute, 93 sub-acute, 44 chronic, 236 acute on chronic) were divided into 5-HT3RA group (n = 105) and control group (n = 314). 5-HT3RAs were associated with decreased 28 days (HR 0.18, 95% CI 0.10-0.34, p < 0.001) and 90 days (HR 0.21, 95% CI 0.13-0.33, p < 0.001) mortality. After propensity score matching (PSM) (n = 67 in each group), 5-HT3RAs were still significantly associated with reduced 28 days (HR 0.10, 95%CI 0.04-0.26, p < 0.001) and 90 days (HR 0.16, 95%CI 0.08-0.31, p < 0.001) mortality. 5-HT3RA group patients had significantly higher 28 and 90 days survivals than controls both before and after PSM (all p < 0.001). This study shows that 5-HT3RAs are associated with increased survival of liver failure patients and thus may be used to treat liver failure if the findings are confirmed by additional studies.
History
References
- https://doi.org//10.1016/j.intimp.2019.106158
- https://doi.org//10.1016/j.jhep.2014.11.045
- https://doi.org//10.1016/j.jhep.2017.06.009
- https://doi.org//10.1016/j.jhep.2013.12.019
- https://doi.org//10.1111/1440-1681.12373
- https://doi.org//10.1152/ajpgi.00448.2016
- https://doi.org//10.1007/s12072-019-09992-x
- https://doi.org//10.1053/j.gastro.2020.04.077
- https://doi.org//10.1109/JBHI.2020.3033405
- https://doi.org//10.1016/j.ejphar.2007.01.028
- https://doi.org//10.1080/03009740410006998
- https://doi.org//10.1080/03009740410006952
- https://doi.org//10.1111/j.1476-5381.1997.tb06789.x
- https://doi.org//10.1080/13813455.2019.1640743
- https://doi.org//10.1002/hep.30361
- https://doi.org//10.1016/j.brainresbull.2016.04.018
- https://doi.org//10.1124/jpet.111.181834
- https://doi.org//10.1111/j.1478-3231.2006.01429.x
- https://doi.org//10.1053/j.gastro.2017.03.023
- https://doi.org//10.1139/cjpp-2019-0551
- https://doi.org//10.3390/jcm8091380
- https://doi.org//10.1002/hep.22177
- https://doi.org//10.1097/MEG.0000000000000750
- https://doi.org//10.1016/j.resuscitation.2010.11.007
- https://doi.org//10.3760/cma.j.issn.1007-3418.2019.01.006
- https://doi.org//10.1111/bph.13006
- https://doi.org//10.1002/hep.31012
- https://doi.org//10.1016/j.lfs.2020.117452
- https://doi.org//10.1016/j.cld.2018.01.010
- https://doi.org//10.1016/j.jhep.2019.11.009
- https://doi.org//10.1007/s43440-020-00146-7
- https://doi.org//10.1111/jphp.13278
- https://doi.org//10.1016/j.bpg.2013.06.012
- https://doi.org//10.1007/s12072-019-09946-3
- https://doi.org//10.1007/s12072-014-9580-2
- https://doi.org//10.3390/ijms20061488
- https://doi.org//10.1016/j.intimp.2012.05.013
- https://doi.org//10.1016/j.bcp.2005.04.031
- https://doi.org//10.1186/s12985-016-0536-0
- https://doi.org//10.3748/wjg.v20.i16.4745
CC BY 4.0